Takeda and Denali team up in neurodegenerative diseases [Seeking Alpha]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Seeking Alpha
Takeda and Denali team up in neurodegenerative diseasesTakeda Pharmaceutical Company (OTCPK:TKPHF)(OTCPK:TKPYY) enters into a strategic option and collaborationagreement with Denali Therapeutics (Pending:DNLI) to develop and commercialize up to three therapies to treat neurodegenerative diseases, including Alzheimer's.Under the terms of the deal, Takeda will pay Denali $150M in upfront payments and purchase of Denali stock, up to $90M in preclinical milestones and opt-in payments.Denali will be responsible for all development and costs prior to IND filings. Takeda has the option to co-develop and co-commercialize each of the three programs. If it elects to do so, the companies will jointly conduct clinical development and equally share costs. They will jointly commercialize products in the U.S. and China while Takeda will have exclusive commercialization rights elsewhere. Global profits will be shared equally.Click to subscribe to real-time analytics on DNLINow read:Daily Insider Rati
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- Denali Therapeutics Inc. (NASDAQ: DNLI) had its price target lowered by analysts at UBS Group AG from $70.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio SciencesPR Newswire
- Gain Therapeutics gets new chief medical officer [Seeking Alpha]Seeking Alpha
- Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
DNLI
Earnings
- 2/27/24 - Miss
DNLI
Sec Filings
- 4/17/24 - Form 4
- 4/15/24 - Form 144
- 4/2/24 - Form 4
- DNLI's page on the SEC website